检索结果-南通市图书馆

Transarterial chemoembolization with drug-eluting beads in hepatocellular carcinoma

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2016年第40期22卷 8853-8861页

作者： Hee Chul Nam Bohyun Jang myeong jun song Department of Internal Medicine College of Medicine the Catholic University of Korea Division of Hepatology Department of Internal Medicine Daejeon St. Mary’s Hospital College of Medicine The Catholic University of Korea

Transarterial chemoembolization(TACE) is a widely used standard treatment for patients with hepatocellular carcinoma(HCC) who are not suitable candidates for curative treatments. The rationale for TACE is that intra-arterial chemotherapy using lipiodol and chemotherapeutic agents, followed by selective vascular embolization, results in a strong cytotoxic effect as well as ischemia(conventional TACE). Recently, drugeluting beads(DC Beads?) have been developed for transcatheter treatment of HCC to deliver higher doses of the chemotherapeutic agent and to prolong contact time with the tumor. DC Beads? can actively sequester doxorubicin hydrochloride from solution and release it in a controlled sustained fashion. Treatment with DC Beads? substantially reduced the amount of chemotherapeutic agent that reached the systemic circulation compared with conventional, lipiodol-based regimens, significantly reducing drug-related adverse events. In this article, we describe the treatment response, survival, and safety of TACE used with drugeluting beads for the treatment of HCC and discuss future therapeutic possibilities.

关键词： Hepatocellular carcinoma Transarterial chemoembolization Conventional TACE Drug-eluting beads Treatment response

A systematic correlation between morphology of porous carbon cathode and electrolyte in lithium-sulfur battery

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Journal of Energy Chemistry 2021年第10期30卷 561-573,I0014页

作者： Jihyeon Park Seoyoung Yoon Seoyeah Oh Jiyoon Kim Dongjun Kim Geonho Kim Jiyeon Lee myeong jun song Ilto Kim Kwonnam Sohn Jiwon Kim School of Integrated Technology College of EngineeringYonsei University85 Songdogwahak-roYeonsu-guIncheon 21983Republic of Korea Integrated Science and Engineering Division Underwood International CollegeYonsei University85 Songdogwahak-roYeonsu-guIncheon 21983Republic of Korea Integrated Biotechnology and Translational Medicine Graduate SchoolYonsei University85 Songdogwahak-roYeonsu-guIncheon 21983Republic of Korea LG Chem. LG Science Park30 Magokjungang 10-roGangseo-guSeoul 07796Republic of Korea

Porous carbon has been applied for lithium-sulfur battery cathodes,and carbonized metal-organic framework(MOF)is advantageous in tuning the ***,we have systematically synthesized water-distorted MOF(WDM)derived porous carbon via controlling the proportion of both water in a mixed solvent(dimethylformamide and water)and ligand in MOF-5 precursors(metal and ligand),which is categorized by its morphology(*** stone(closed),Tassel(open)and Intermediate(semi-open)).For example,decrease in water and increase in ligand content induce Cracked stone WDMs which showed the highest specific surface area(2742-2990 m^(2)/g)and pore volume(2.81-3.28 cm^(3)/g)after *** effect of carbonized WDMs(CWDMs)on battery performance was examined by introducing electrolytes with different sulfur reduction mechanisms(***/DME and ACN_(2) LiTFSITTE):Closed framework effectively confines polysulfide,whereas open framework enhances electrolyte *** initial capacities of the batteries were in the following order:Cracked stone>Intermediate>Tassel for DOL/DME and Intermediate>Tassel>Cracked stone for ACN_(2) *** note,Intermediate CWDM exhibited the highest initial capacity and retained capacity after 100 cycles(1398 and 747 mAh/g)in ACN_(2) LiTFSI-TTE electrolyte having advantages from both open and closed *** sum,we could correlate cathode morphology(openness and pore structure)and electrolyte type(*** solubility)with lithium-sulfur battery performance.

关键词： Lithium-sulfur battery Metal-organic framework Hierarchical porous carbon cathode Morphology control Electrolyte Lithium polysulfide solubility

Durability of viral response after off-treatment in HBeAg positive chronic hepatitis B

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2012年第43期18卷 6277-6283页

作者： myeong jun song Do Seon song Hee Yeon Kim Sun Hong Yoo Si Hyun Bae Jong Young Choi Seung Kew Yoon Yong-Han Paik june Sung Lee Hyun Woong Lee Hyung Joon Kim Departments of Internal Medicine College of Medicine The Catholic University of Korea Seoul 137-040 South Korea Departments of Internal Medicine Samsung Medical Center Sungkyunkwan University School of Medicine Seoul 135-710 South Korea Departments of Internal Medicine College of Medicine Inje University Ilsan Paik Hospital of The Korea Goyang-si 411-706 South Korea Departments of Internal Medicine College of Medicine The Chung-Ang University of Korea Seoul 156-755 South Korea

AIM:To evaluate the durability in hepatitis B e antigen (HBeAg) positive chronic hepatitis B patients who discontinued antiviral treatment. METHODS:A total of 48 HBeAg positive chronic hepatitis B patients who were administered nucleoside analogues and maintained virological response for ≥ 6 mo [hepatitis B virus (HBV) DNA 104 copies/mL after HBeAg seroconversion with previously undetectable HBV-DNA level. RESULTS:During the median follow-up period of 18.2 mo (range:5.1-47.5 mo) after cessation of antiviral treatment, the cumulative serological recurrence rate was 15 % at 12 mo. The median duration between the cessation of antiviral treatment and serologic recurrence was 7.2 mo (range:1.2-10.9 mo). Of the 48 patients with HBeAg positive chronic hepatitis, 20 (41.6%) showed virological recurrence. The cumulative virologic recurrence rates at 12 mo after discontinuing the antiviral agent were 41%. The median duration between off-treatment and virologic recurrence was 7.6 mo (range:4.3-27.1 mo). The mean age of the virological recurrence group was older than that of the non-recurrence group (46.7 ± 12.1 years vs 38.8 ± 12.7 years, respectively; P = 0.022). Age (> 40 years) and the duration of consolidation treatment (≥ 15 mo) were significant predictive factors for offtreatment durability in the multivariate analysis [P = 0.049, re

关键词： Durability Seroconversion Chronic hepatitis B Hepatitis B e antigen positive Recurrence Consolidation

Hepatic arterial infusion chemotherapy in hepatocellular carcinoma with portal vein tumor thrombosis

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2013年第29期19卷 4679-4688页

作者： Do Seon song Si Hyun Bae myeong jun song Sung Won Lee Hee Yeon Kim Young Joon Lee jung Suk Oh Ho Jong Chun Hae Giu Lee Jong Young Choi Seung Kew Yoon Department of Internal Medicine College of Medicine The Catholic University of Korea Seoul 137-040 South Korea Department of Radiology College of Medicine The Catholic University of Korea Seoul 137-040 South Korea

AIM: To evaluate the prognostic factors and efficacy of hepatic arterial infusion chemotherapy in hepatocellular carcinoma with portal vein tumor thrombosis. METHODS: Fifty hepatocellular carcinoma (HCC) patients with portal vein tumor thrombosis (PVTT) were treated using hepatic arterial infusion chemotherapy (HAIC) via a subcutaneously implanted port. The epirubicin-cisplatin-5-fluorouracil (ECF) chemotherapeutic regimen consisted of 35 mg/m 2 epirubicin on day 1, 60 mg/m 2 cisplatin for 2 h on day 2, and 500 mg/m 2 5-fluorouracil for 5 h on days 1-3. The treatments were repeated every 3 or 4 wk. RESULTS: Three (6%) of the 50 patients achieved a complete response (CR), 13 (26%) showed partial responses (PR), and 22 (44%) had stable disease (SD).The median survival and time to progression were 7 and 2 mo, respectively. After 2 cycles of HAIC, CR was achieved in 1 patient (2%), PR in 10 patients (20%) and SD in 26 patients (52%). Significant pre-treatment prognostic factors were a tumor volume of < 400 cm 3 (P = 0.01) and normal levels of protein induced by vitamin K absence or antagonist (PIVKA)-Ⅱ (P = 0.022). After 2 cycles of treatment, disease control (CR + PR + SD) (P = 0.001), PVTT response (P = 0.003) and α-fetoprotein reduction of over 50% (P = 0.02) were independent factors for survival. Objective response (CR + PR), disease control, PVTT response, and combination therapy during the HAIC were also significant prognostic factors. Adverse events were tolerable and successfully managed. CONCLUSION: HAIC may be an effective treatment modality for advanced HCC with PVTT in patients with tumors < 400 cm 3 and good prognostic factors.

关键词： Hepatocellular carcinoma Hepatic arterial infusion chemotherapy Portal vein tumor thrombosis

Safety and efficacy of tenofovir in chronic hepatitis B-related decompensated cirrhosis

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2017年第13期23卷 2396-2403页

作者： Soon Kyu Lee myeong jun song Seok Hyun Kim Byung Seok Lee Tae Hee Lee Young Woo Kang Suk Bae Kim Il Han song Hee Bok Chae Soon Young Ko Jae Dong Lee Division of Hepatology Department of Internal MedicineDaejeon St.Mary's HospitalCollege of MedicineThe Catholic University of Korea Department of Internal Medicine Chungnam University Hospital Department of Internal Medicine Konyang University Hospital Department of Internal Medicine Dankook University Hospital Department of Internal Medicine Chung Buk University Hospital Department of Internal Medicine Konkuk University Chungju Hospital

AIM To evaluate the safety and efficacy of tenofovir disoproxil fumarate(TDF) as a first-line therapy in decompensated liver disease. METHODS We enrolled 174 chronic hepatitis B-related liver cirrhosis patients treated with 300 mg/d TDF at six Korean centers. Of the 174 cirrhosis patients, 57 were assigned to the decompensated cirrhosis group and 117 were assigned to the compensated cirrhosis group. We followed the patients for 12 mo and evaluated clinical outcomes, including biochemical, virological, and serological responses. We also evaluated changes in hepatic and renal function and compared the decompensated and compensated cirrhosis groups. RESULTS The 1-year complete virological response(CVR) and Hepatitis B e antigen(HBe Ag) seroconversion were seen in 70.2% and 14.2% in the decompensated cirrhosis group, respectively. The rates of HBe Ag seroconversion/loss and ALT normalization at month 12 were similar in both groups. TDF treatment was also effective for decreasing the level of hepatitis B virus(HBV) DNA in both groups, but CVR was higher in the compensated group(88.9% vs 70.2%, P = 0.005). Tenofovir treatment for 12 mo resulted in improved Child-Turcotte-Pugh(CTP) and model for end-stage liver disease(MELD) scores in decompensated group(P < 0.001). Of the 57 decompensated patients, 39(68.4%) achieved CTP class A and 27(49.1%) showed improvement in the CTP score of 2 points after 12 mo of TDF. The observed rate of confirmed 0.5 mg/d L increases in serum levels of creatinine in the decompensated and compensated cirrhosis group were 7.0% and 2.5%, respectively(P < 1.000).CONCLUSION TDF therapy in decompensated cirrhosis patients was effective for decreasing HBV DNA levels and improving hepatic function with relatively lower CVR than in compensated cirrhosis. Thus, physicians should carefully monitor not only renal function but also treatment responses when using TDF in decompensated cirrhosis patients.

关键词： Tenofovir Decompensated liver cirrhosis Compensated liver cirrhosis Virological response Renal safety

Predictive value of ^(18)F-fluorodeoxyglucose PET/CT for transarterial chemolipiodolization of hepatocellular carcinoma

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2012年第25期18卷 3215-3222页

作者： myeong jun song Si Hyun Bae Ie Ryung Yoo Chung-Hwa Park Jeong Won Jang Ho Jong Chun Byung Gil Choi Hae Giu Lee Jong Young Choi Seung Kew Yoon Department of Internal Medicine College of MedicineThe Catholic University of KoreaSeoul 137-040South Korea Department of Nuclear Medicine College of MedicineThe Catholic University of KoreaSeoul 137-040South Korea Department of Radiology College of MedicineThe Catholic University of KoreaSeoul 137-040South Korea

AIM： To investigate the correlation of 18F-fluorodeoxy- glucose （18F-FDG） positron emission tomography （PET） with clinical features and the prediction of treatment response. METHODS： A total of 83 hepatocellular carcinoma （HCC） patients undergoing 18F-FDG PET before transar- terial chemolipiodolization with systemic chemo-infusion between October, 2006 and May, 2009 were retrospec-tively enrolled. The patients included 68 men and 15 women （mean age, 60 ~ 10.7 years）. The effect of 18F- FDG-monitored PET uptake on clinical features and on the evaluated treatment response was ascertained with modified Response Evaluation Criteria in Solid Tumors. The PET parameters of maximal standardized uptake value of the tumor （Tsuvmax）, the ratio of the tumor maximal standardized uptake value （SUV） to the liver maximal SUV （Tsuvmax/Lsuwax） and the ratio of tumor maximal SUV to the liver mean SUV （msuvmax/LSUVrnean） were tested as predictive factors. RESULTS： Among the 3 SUV parameters, the TSUV- =maxdLsuvmean ratio （cutoff value of 1.90） was significantly associated with tumor burden including tumor size, tu- mor number, α-fetoprotein levels and tumor stage （P 〈 0.001, P = 0.008, P = 0.011, P 〈 0.001, respectively）. The objective response rates in patients with a high SUV ratio （≥ 1.90） were significantly better than those with a low SUV ratio （〈 1.90）（P = 0.020）. The overall survival rates of patients exhibiting a low Tsuvmax/Lsu- Vmean ratio （〈 1.90） and those with a high SUV ratio （≥1.90） was 38.2 and 10.3 mo, respectively （P 〈 0.01）. However, the time to progression showed no significant difference between the groups （P = 0.15）. CONCLUSION： 18F-FDG PET can be an important predictor of HCC treatment. In particular, the Tsuvmax/ Lsuwean ratio （cutoff value of 1.90） can provide useful information in treatment prognosis for HCC patients treated with Iocoregional therapy.

关键词： 18F-fluorodeoxyglucose positron emissiontomography Transarterial chemolipiodolization withsystemic chemo-infusion Treatment response Predic-tive factor, Overall survival

Outcome of transarterial chemoembolization-based multi-modal treatment in patients with unresectable hepatocellular carcinoma

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2015年第8期21卷 2395-2404页

作者： Do Seon song Soon Woo Nam Si Hyun Bae Jin Dong Kim Jeong Won Jang myeong jun song Sung Won Lee Hee Yeon Kim Young Joon Lee Ho Jong Chun Young Kyoung You Jong Young Choi Seung Kew Yoon Department of Internal Medicine College of Medicine The Catholic University of Korea Department of Internal Medicine Cheju Halla General Hospital Department of Radiology College of Medicine The Catholic University of Korea Department of Surgery College of Medicine The Catholic University of Korea

AIM:To investigate the efficacy and safety of transarterial chemoembolization(TACE)-based multimodal treatment in patients with large hepatocellular carcinoma(HCC).METHODS:A total of 146 consecutive patients were included in the analysis,and their medical records and radiological data were reviewed ***:In total,119 patients received TACE-based multi-modal treatments,and the remaining 27 received conservative *** survival(P<0.001)and objective tumor response(P=0.003)were significantly better in the treatment group than in the conservative *** subgroup analysis,survival benefits were observed not only in the multi-modal treatment group compared with the TACE-only group(P=0.002)but also in the surgical treatment group compared with the loco-regional treatment-only group(P<0.001).Multivariate analysis identified tumor stage(P<0.001)and tumor type(P=0.009)as two independent pre-treatment factors for *** adjusting for significant pre-treatment prognostic factors,objective response(P<0.001),surgical treatment(P=0.009),and multi-modal treatment(P=0.002)were identified as independent post-treatment prognostic ***:TACE-based multi-modal treatments were safe and more beneficial than conservative *** surgery after successful downstaging resultedin long-term survival in patients with large,unresectable HCC.

关键词： Hepatocellular carcinoma Multimodal treatment Tran

Gamma-glutamyl transferase and cardiovascular risk in nonalcoholic fatty liver disease:The Gut and Obesity Asia initiative

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2020年第19期26卷 2416-2426页

作者： Panyavee Pitisuttithum Wah-Kheong Chan George Boon-Bee Goh Jian-Gao Fan myeong jun song Phunchai Charatcharoenwitthaya Ajay Duseja Yock-Young Dan Kento Imajo Atsushi Nakajima Khek-Yu Ho Khean-Lee Goh Vincent Wai-Sun Wong Sombat Treeprasertsuk Department of Medicine Faculty of MedicineChulalongkorn UniversityBangkok 10330Thailand Department of Medicine University of MalayaKuala Lumpur 50603Malaysia Department of Gastroenterology&Hepatology Singapore General HospitalSingapore 169608Singapore Department of Gastroenterology Shanghai Jiao Tong University School of MedicineShanghai 200092China Department of Internal Medicine The Catholic University of KoreaDaejeon 301-723South Korea Division of Gastroenterology Faculty of Medicine Siriraj HospitalMahidol UniversityBangkok 10700Thailand Department of Hepatology Post Graduate Institute of Medical Education and ResearchChandigarh 160012India Department of Medicine National University of Singapore 119228Singapore Department of Gastroenterology and Hepatology Yokohama City University Graduate School of MedicineYokohama 236-0004Japan Department of Medicine and Therapeutics The Chinese University of Hong KongHong Kong 999077China

BACKGROUND Gamma-glutamyl transferase(GGT)is associated with the risk of cardiovascular disease(CVD)in the general *** To identify the association of baseline GGT level and QRISK2 score among patients with biopsy-proven nonalcoholic fatty liver disease(NAFLD).METHODS This was a retrospective study involving 1535 biopsy-proven NAFLD patients from 10 Asian centers in 8 countries using data collected by the Gut and Obesity in Asia(referred to as“GO ASIA”)*** patients with available baseline GGT levels and all 16 variables for the QRISK2 calculation(QRISK2-2017;developed by researchers at the United Kingdom National Health Service;https://***/2017/;10-year cardiovascular risk estimation)were included and compared to healthy controls with the same age,sex,and *** risk was ***2 score>10%was defined as the high-CVD-risk *** stages 3 and 4(F3 and F4)were considered advanced *** A total of 1122 patients(73%)had complete data and were included in the final analysis;314(28%)had advanced *** median age(interquartile range[IQR])of the study population was 53(44-60)years,532(47.4%)were females,and 492(43.9%)were of Chinese *** median 10-year CVD risk(IQR)was 5.9%(2.6-10.9),and the median relative risk of CVD over 10 years(IQR)was 1.65(1.13-2.2)compared to healthy individuals with the same age,sex,and *** high-CVD-risk group was significantly older than the low-risk group(median[IQR]:63[59-67]vs 49[41-55]years;P<0.001).Higher fibrosis stages in biopsy-proven NAFLD patients brought a significantly higher CVD risk(P<0.001).Median GGT level was not different between the two groups(GGT[U/L]:Median[IQR],high risk 60[37-113]vs low risk 66[38-103],P=0.56).There was no correlation between baseline GGT level and 10-year CVD risk based on the QRISK2 score(r=0.02).CONCLUSION The CVD risk of NAFLD patients is higher than that of healthy *** GGT level cannot predict CVD ri

关键词： Nonalcoholic fatty liver disease Gamma glutamyl transferase QRISK Cardiovascular risk Gut and Obesity in Asia

Photothermal probiotics delivery of photodynamic agents for enhanced immunogenic cell death within hypoxia center of solid tumors

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Nano Research 2025年第1期18卷 642-652页

作者： Wen Luo Shiyu Du Yateng Jiang Bangshun He jun Tang Jingjing Yang Yujun song Jiangsu Key Laboratory of Artificial Functional Materials State Key Laboratory of Analytical Chemistry for Life ScienceNational Laboratory of Solid State MicrostructuresCollege of Engineering and Applied SciencesNanjing UniversityNanjing 210023China Department of Laboratory Medicine Nanjing First HospitalNanjing Medical UniversityNanjing 210006China Department of Anesthesiology Jinling HospitalMedical School of Nanjing UniversityNanjing 210000China Department of Biochemistry and Molecular Biology School of Medicine&Holistic Integrative MedicineJiangsu Collaborative Innovation Center of Chinese Medicinal Resources IndustrializationNanjing University of Chinese MedicineNanjing 210023China

Resulting from harsh hypoxic environmental conditions,central cells in the core of solid tumors are usually more aggressive and malignant with a less stable ***,therapeutic agents with improved penetration for the activation of immunity in tumor centers exhibit promising potential in ***,polydopamine-coated Escherichia coli Nissle 1917(EcN)bearing chlorin e6(Ce6)-loaded and polyethyleneimine(PEI)-coated hollow manganese dioxide(shorted as EP-ChP)are applied for enhanced immunotherapy in deep *** accumulation in tumor center through hypoxia targeting,manganese dioxide is degradated under the tumor microenvironment with released Ce6 and thus generates reactive oxygen species(ROS)upon 660 nm laser irradiation,which can further lower thermalresistance of cancer cells via HSP90α*** to that,heating induced by polydopamine upon 808 nm laser irradiation can achieve effective tumor *** upon dual laser induces enhanced immunogenic cell death,while bacterial infections in tumor tissues also trigger innate *** bacteria-based approach provides enhanced antitumor immune responses in deep tumors with great potential in the reshaping of immunosuppression tumor microenvironment.

关键词： bacteria phototherapies immunotherapy hypoxia targeting tumor penetration